QuickView: From llama to laboratory
arGEN-X's novel approach to developing therapeutic antibodies has already generated five candidates. The €42m proceeds from the July 2014 IPO (4.9m shares sold at €8.5) will enable it to develop ARGX-110, ARGX-111 and ARGX-113 through to Phase I or beyond, and attract development partners for larger indications. The 12-month outlook should see a flow of clinical trial data in H215 and the progress of ARGX-113 into the clinic.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.